2024
Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F, Davanzo G, de Brito Monteiro L, Muraro S, de Souza G, Morari J, Galdino F, Brunetti N, Reis-de-Oliveira G, Carregari V, Nadruz W, Martins-de-Souza D, Farias A, Velloso L, Proenca-Modena J, Mori M, Loh W, Bhatt D, Yellon D, Davidson S, De Oliveira P, Moraes-Vieira P, Sposito A. Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study. Frontiers In Pharmacology 2024, 15: 1402032. PMID: 39434905, PMCID: PMC11491754, DOI: 10.3389/fphar.2024.1402032.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsSARS-CoV-2 infectionSARS-CoV-2Viral replicationInflammatory responseInflammasome activationMarkers of inflammasome activationPlacebo-controlled studySuppress viral replicationBlood mononuclear cellsInfection in vitroPrimary metabolitesCOVID-19 patientsDouble-blindPrimary endpointHealthy volunteersSevere acute respiratory syndrome coronavirus 2Plasma markersAcute respiratory syndrome coronavirus 2Mononuclear cellsClinical trialsRespiratory syndrome coronavirus 2Day 2Syndrome coronavirus 2
2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial
Sposito A, Breder I, Barreto J, Breder J, Bonilha I, Lima M, Oliveira A, Wolf V, Luchiari B, do Carmo H, Munhoz D, Oliveira D, Coelho-Filho O, Coelho O, Matos-Souza J, Moura F, de Carvalho L, Nadruz W, Quinaglia T, Kimura-Medorima S. Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial. Cardiovascular Diabetology 2022, 21: 147. PMID: 35933413, PMCID: PMC9356512, DOI: 10.1186/s12933-022-01584-8.Peer-Reviewed Original ResearchConceptsFlow-mediated dilationEndothelial functionPost-treatment changesPlasma levelsPlasma levels of nitric oxide metabolitesBackgroundSodium-glucose cotransporter 2 inhibitorsCardiovascular eventsInhibitors reduce cardiovascular eventsLevels of nitric oxide metabolitesE groupPlasma levels of nitrateEE groupHigh-risk patientsProprotein convertase subtilisin/kexin 9Nitric oxide metabolitesRandomized active-controlled trialActive-controlled trialReduce cardiovascular eventsType 2 diabetesPCSK9-iSGLT2i treatmentPrimary endpointSGLT2-iEndothelial dysfunctionSecondary outcomes